Bortezomib, Liposome Doxorubicin and Dexamethasone (PDd) is Superior in Safety and Not Inferior in Efficiency to Bortezomib, Doxorubicin and Dexamethasone (PAd) As Induction Therapy in New-Diagnosed Multiple Myeloma Patients
Bortezomib, doxorubicin and dexamethasone (PAd) and bortezomib, liposome doxorubicin and dexamethasone (PDd) are widely used as induction chemotherapy regimens in China in the new-diagnosed multiple myeloma patients before autologous stem cell transplantation. There was no data on the comparison in safety and efficiency between those two regimens, so we designed this open-label, randomized, multicenter clinical trial in 10 centers in China (NCT02577783).
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Yan Shuang, Jingjing Shang, Lingzhi Yan, Song Jin, Depei Wu, Chengcheng Fu Source Type: research
More News: Chemotherapy | China Health | Clinical Trials | Dexamethasone | Hematology | Leukemia | Lymphoma | Myeloma | Stem Cell Therapy | Stem Cells | Transplants | Velcade